Given that the most common cause of acquired resistance to EGFR-TKIs in EGFR-mutant NSCLC is T790 M mutation, vorinostat may be not sufficient to overcome T790 M-related resistance to EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.